Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study

被引：1
|
作者：
Sternberg, C. N. [1 ,2 ]
Scher, H. I. [3 ]
Molina, A. [4 ]
North, S. [5 ]
Mainwaring, P. [6 ,7 ]
Hao, Y. [8 ]
Gagnon, D. [9 ]
Kheoh, T. [4 ]
Haqq, C. M. [4 ]
de Bono, J. [10 ,11 ]
机构：
[1] San Camillo Hosp, Dept Med Oncol, Rome, Italy
[2] Forlanini Hosp, Dept Med Oncol, Rome, Italy
[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[4] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
[5] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[6] Haematol Clin Australasia, Milton, MA, Australia
[7] Oncol Clin Australasia, Milton, MA, Australia
[8] Johnson & Johnson Pharmaceut Serv, Global Strateg Mkt & Market Access, Raritan, NJ USA
[9] Thomson Reuters, Strateg Consulting Healthcare, Santa Barbara, CA USA
[10] Inst Canc Res, Sutton, Surrey, England
[11] Royal Marsden Hosp, Med Sect, Sutton, Surrey, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71966-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [11] Effect of concomitant medication use on outcomes of ties and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Hamilton, Robert James
    Li, Jinhui
    Naini, Vahid
    San Kheoh, Thian
    De Porre, Peter
    Molina, Arturo
    Lelbowitz-Amit, Raya
    De Bono, Johann Sebastian
    Scher, Howard I.
    Ryan, Charles J.
    Chi, Kim N.
    Joshua, Anthony M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [12] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [13] When the time matters: Metastatic Castration Resistant Prostate Cancer (mCRPC) patients long responders to Abiraterone acetate (AA) in post-docetaxel setting
    Procopio, G.
    Porcu, L.
    Grassi, P.
    De Giorgi, U.
    Galli, L.
    Caffo, O.
    Boccardo, F.
    Facchini, G.
    De Vincenzo, F.
    Zaniboni, A.
    Chiuri, V.
    Fratino, L.
    Santini, D.
    Adamo, V.
    De Vivo, R.
    Di Nota, A.
    Messina, C.
    Ricotta, R.
    de Braud, F.
    Verzoni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 59 - 59
  • [14] Effect of abiraterone acetate (AA) on patient-reported pain in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: Results of longitudinal sensitivity analyses.
    Hao, Yanni
    Cleeland, Charles S.
    Gagnon, Dennis
    Espindle, Derek
    Molina, Arturo
    Basch, Ethan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [15] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [16] Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
    Van Praet, Charles
    Rottey, Sylvie
    Van Hende, Fransien
    Pelgrims, Gino
    Demey, Wim
    Van Aelst, Filip
    Wynendaele, Wim
    Gil, Thierry
    Schatteman, Peter
    Filleul, Bertrand
    Schallier, Dennis
    Machiels, Jean-Pascal
    Schrijvers, Dirk
    Everaert, Els
    D'Hondt, Lionel
    Werbrouck, Patrick
    Vermeij, Joanna
    Mebis, Jeroen
    Clausse, Marylene
    Rasschaert, Marika
    Van Erps, Joanna
    Verheezen, Jolanda
    Van Haverbeke, Jan
    Goeminne, Jean-Charles
    Lumen, Nicolaas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 254.e7 - 254.e13
  • [17] Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy
    Scher, H. I.
    Logothetis, C.
    Molina, A.
    Goodman, O. B.
    Sternberg, C. N.
    Chi, K. N.
    Kheoh, T. S.
    Haqq, C. M.
    Fizazi, K.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [18] Final analysis of the randomised, phase 3, COU-AA-302 study of abiraterone acetate (AA) in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    De Souza, P.
    Smith, M. R.
    Fizazi, K.
    Saad, F.
    Mulders, P. F. A.
    Sternberg, C. N.
    Miller, K.
    Logothetis, C. J.
    Shore, N.
    Small, E. J.
    Carles, J.
    Flaig, T. W.
    Taplin, M-E.
    Higano, C. S.
    De Bono, J. S.
    Griffin, T. W.
    De Porre, P.
    Yu, M. K.
    Park, Y. C.
    Li, J.
    Kheoh, T.
    Naini, V.
    Molina, A.
    Rathkopf, D. E.
    Ryan, C. J.
    BJU INTERNATIONAL, 2015, 115 : 21 - 22
  • [19] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [20] Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Fizazi, Karim
    Scher, Howard I.
    Molina, Arturo
    Logothetis, Christopher J.
    Chi, Kim N.
    Jones, Robert J.
    Staffurth, John N.
    North, Scott
    Vogelzang, Nicholas J.
    Saad, Fred
    Mainwaring, Paul
    Harland, Stephen
    Goodman, Oscar B., Jr.
    Sternberg, Cora N.
    Li, Jin Hui
    Kheoh, Thian
    Haqq, Christopher M.
    de Bono, Johann S.
    LANCET ONCOLOGY, 2012, 13 (10): : 983 - 992
12345